Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

(2011) Michel Delforge et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

(2010) E. Terpos et al.   ANNALS OF ONCOLOGY

First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro

(2010) Thomas Lund et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

(2009) E. Terpos et al.   ANNALS OF ONCOLOGY

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment

(2008) Ulrike Heider et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

(2008) Siddhartha Mukherjee et al.   JOURNAL OF CLINICAL INVESTIGATION

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

(2008) E Terpos et al.   LEUKEMIA

Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions

(2008) P. Boissy et al.   LEUKEMIA RESEARCH